References

Aalto-Setälä K, Gylling H, Helve E, Kovanen P, Miettinen TA, Turtola H & Kontula K (1989b) Genetic polymorphism of the apolipoprotein B gene locus influences serum LDL cholesterol level in familial hypercholesterolemia. Hum Genet 82(4): 305-307.

Aalto-Setälä K, Gylling H, Miettinen T & Kontula K (1988a) Identification of a deletion in the LDL receptor gene A Finnish type of mutation. Febs Letters 230: 31-34.

Aalto-Setälä K, Helve E, Kovanen PT & Kontula K (1989a) Finnish type of low density lipoprotein receptor gene mutation (FH-Helsinki) deletes exons encoding the carboxy-terminal part of the receptor and creates an internalization-defective phenotype. J Clin Invest 84: 499-505.

Aalto-Setälä K, Tikkanen MJ, Taskinen MR, Nieminen M, Holmberg P & Kontula K (1988b) XbaI and c/g polymorphisms of the apolipoprotein B gene locus are associated with serum cholesterol and LDL-cholesterol levels in Finland. Atherosclerosis 74(1-2): 47-54.

Aburatani H, Matsumoto A, Itoh H, Yamada N, Murase T, Takaku F & Itakura H (1988) A study of DNA polymorphism in the apolipoprotein B gene in a Japanese population. Atherosclerosis 72(1): 71-76.

Amouyel P, Isorez D, Bard J, Goldman M, Lebel P, Zylberberg G & Fruchart JC (1993) Parental history of early myocardial infarction is associated with decreased levels of lipoparticle AI in adolescents. Arterioscler Thromb 13: 1640-1644.

de Andrade M, Thandi I, Brown S, Gotto A Jr, Patsch W & Boerwinkle E (1995) Relationship of the apolipoprotein E polymorphism with carotid artery atherosclerosis. Am J Hum Genet 56:1379-1390.

Angelin B (1997) Therapy for lowering lipoprotein (a) levels. Curr Opin Lipidol 8(6): 337-41.

Armstrong VW, Cremer P, Eberle E, Manke A, Schulze F, Wieland H, Kreuzer H & Seidel D (1986) The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis; Atherosclerosis 62:249-257

Austin MA (1991) Plasma triglyceride and coronary heart disease. Arterioscler Thromb 11: 2-14.

Austin MA, Sandholzer C, Selby JV, Newman B, Krauss RM & Utermann G (1992) Lipoprotein (a) in women twins: Heritability and relationship to apolipoprotein(a) phenotypes. Am J Hum Genet 51: 829-840.

de Backer G, de Bacquer D & Kornitzer M (1998) Epidemiological aspects of high density lipoprotein cholesterol. Atherosclerosis 137 Suppl: S1-6.

Ballantyne CM (1998) Current thinking in lipid lowering. Am J Med 104(6A): 33S-41S.

Berg K (1986) DNA polymorphism at the apolipoprotein B locus is associated with lipoprotein level. Clin Genet 30(6): 515-520 .

Berg K & Mohr J (1963) Genetics of the Lp system. Acta genet 13(4): 349-360.

Berglund L, Wiklund O, Eggertsen G, Olofsson SO, Eriksson M, Lindén T, Bondjers G & Angelin B (1993) Apolipoprotein E phenotypes in familial hypercholesterolaemia: importance for expression of disease and response to therapy. J Intern Med 233(2): 173-178.

Bilheimer DW, Eisenberg S & Levy RJ (1972) The metabolism of very low density lipoprotein proteins. I. Preliminary in vitro and in vivo observations. Biochim Biophys Acta 260(2): 212-221.

Blackhart BD, Ludwig EM, Pierotti VR, Caiati L, Onasch MA, Wallis SC, Powell L, Pease R, Knott TJ, Chu ML, Mahley RW, Scott J, McCarthy BJ & Levy-Wilson B (1986) Structure of the human apolipoprotein B gene. J Biol Chem 261(33):15364-15367.

Blanco-Vaca F, Gaubatz JW, Bren N, Kottke BA Morrisett, JD & Guevara JJr (1994) Identification and quantification of apolipoproteins in addition to apo(a) and apo B-100 in human lipoprotein(a). Chem Phys Lipids 67-68: 35-42.

Blane G F (1989) Review of European clinical experience with fenofibrate. Cardiology 76(suppl.1): 1-13.

Boerwinkle E & Chan L (1989) A three codon insertion/deletion polymorphism in the signal peptide region of the human apolipoprotein B (APOB) gene directly typed by the polymerase chain reaction. Nucleic Acids Res 17(10): 4003.

Boerwinkle E, Brown SA, Rohrbach K, Gotto AM Jr & Patsch W (1991a) Role of apolipoprotein E and B gene variation in determining response of lipid, lipoprotein, and apolipoprotein levels to increased dietary cholesterol. Am J Hum Genet 49:1145-1154.

Boerwinkle E, Chen SH, Visvikis S, Hanis CL, Siest G & Chan L (1991b) Signal peptide-length variation in human apolipoprotein B gene. Molecular characteristics and association with plasma glucose levels. Diabetes 40(11):1539-1544.

Boerwinkle E (1992) genetics of plasma lipoprotein(a) concentrations. Curr Opin Lipidol 3:128-136.

Bolibar I, Thompson GT, von Eckardstein A, Sandkamp M & Assman G (1995) Dose-response relationships of serum lipid measurements with the extent of coronary stenosis. Arterioscler Thromb Vasc Biol 15:1035-1042.

Brown G , Albers JJ, Fisher LD, Schaefer, SM Lin JT, Kaplan C, Zhao XQ, Bisson BD, Fitzpatrick VF & Dodge HT (1990) Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 323: 1289-1298.

Brown MS & Goldstein JL (1986) A receptor-mediated pathway for cholesterol homeostasis. Science 232: 34-47.

Bruce C & Tall AR (1995) Cholesteryl ester transfer proteins, reverse cholesterol transport, and atherosclerosis. Curr Opin Lipidol 6: 306-311.

Bruce C, Davidson WS, Kussie P, Lund-Katz S, Phillips MC, Ghosh R & Tall AR (1995) Molecular determinants of plasma cholesteryl ester transfer protein binding to high density lipoproteins. J Biol Chem 270(19): 11532-11542.

Buring JE, O"Connor GT, Goldhaber SZ, Rosner B, Herbert PN, Blum CB, Breslow JL & Hennekens CH (1992) Decreased HDL2 and HDL3 cholesterol, apo A-I and apo A-II, and increased risk of myocardial infarction. Circulation 85: 22-29.

Böhn M, Bakken A, Erikssen J & Berg K (1994) The apolipoprotein B signal peptide insertion/deletion polymorphism is not associated with myocardial infarction in Norway. Clin Genet 45(5): 255-259.

Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ & Friedewald W (1986) Fifteen year mortality in Coronary Drug Project patients; long-term benefit with niacin. J Am Coll Cardiol 8(6): 1245-1255.

Carlson LA, Hamsten A & Asplund A (1989) Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Intern Med 226: 271-276.

Carmena R, Roederer G, Mailloux H, Lussier-Cacan S & Davignon J (1993) The response to lovastatin treatment in patients with heterozygous familial hypercholesterolemia is modulated by apolipoprotein E polymorphism. Metabolism 42: 895-901.

Chen SH, Habib G, Yang CY, Gu ZW, Lee BR, Weng S, Silberman SR, Cai SJ, Deslypere JP, Rosseneu M, Gotto AM Jr, Li WH & Chan L (1987) Apolipoprotein B-48 is the product of a messenger RNA with an organ-spesific in-frame stop codon. Science 238: 363-366.

Chen SH, Yang CY, Chen PF, Setzer D, Tanimura M, Li WH, Gotto AM Jr & Chan L (1986) The complete cDNA and amino acid sequence of human apolipoprotein B-100. J Biol Chem 261(28): 12918-12921.

Coresh J, Kwiterovich PO Jr, Smith HH & Bachorik PS (1993) Association of plasma triglyceride concentration and LDL particle diameter, density, and chemical composition with premature coronary artery disease in men and women: J Lipid Res 34: 1687-1697.

Criqui MH, Heiss G, Cohn R, Cowan LD, Suchindran CM, Bangdiwala S, Kritchevsky S, Jacobs DR Jr, O´Grady HK & Davis CE (1993) Plasma triglyceride level and mortality from coronary heart disease. N Engl J Med 328: 1220-1225.

Cumming AM & Robertson FW (1984) Polymorphism at the Apoprotein-E locus in relation to risk of coronary disease. Clin Genet 25: 310-313.

Dahlén G, Berg K, Gillnäs T & Ericson C (1975) Lp(a) lipoprotein/pre-beta1-lipoprotein in Swedish middle-aged males and in patients with coronary heart disease. Clin Genet 7: 334-341.

Dahlén GH, Guyton JR, Attar M, Farmer JA, Kautz JA & Gotto AM Jr (1986) Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation 74: 758-765.

Darnfors C, Wiklund O, Nilsson J, Gerard B, Carlsson P, Johansson S, Bondjers G & Bjursell G (1989) Lack of correlation between the apolipoprotein B XbaI polymorphism and blood lipid levels in a Swedish population. Atherosclerosis 75(2-3): 183-188.

Davignon J, Gregg RE & Sing CF (1988) Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 8(1): 1-21.

Deeb SS, Failor RA, Brown BG, Brunzell JD, Albers JJ & Motulsky AG (1986) Molecular genetics of apolipoproteins and coronary heart disease. Cold Spring Harb Symp Quant Biol 51: 403-409.

Demant T, Bedford D, Packard CJ & Shepherd J (1991) Influence of apolipoprotein E polymorphism on apolipoprotein B-100 metabolism in normolipemic subjects. J Clin Invest 88(5): 1490-1501.

Dujovne CA (1997) New lipid lowering drugs and new effects of old drugs. Curr Opin Lipidol 8(6): 362-8.

Dullaart RP, Groener JE, Dikkeschei BD, Erkelens DW & Doorenbos H (1991) Elevated cholesteryl ester transfer protein activity in IDDM men who smoke. Possible factor for unfavorable lipoprotein profile. Diabetes Care 14(4): 338-341.

Dullaart RP, Hoogenberg K, Dikkeschei BD & van Tol A (1994) Higher plasma lipid transfer protein activities and unfavorable lipoprotein changes in cigarette-smoking men. Arterioscler Thromb 14(10): 1581-1585.

Dunning AM, Tikkanen MJ, Ehnholm C, Bütler R & Humphries SE (1988) Relationships between DNA and protein polymorphisms of apolipoprotein B. Hum Genet 78(4): 325-329.

von Eckardstein A, Castro G, Wybranska I, Theret N, Duchateau P, Duverger N, Fruchart JC, Ailhaud G & Assmann G (1993) Interaction of reconstituted high density lipoprotein discs containing human apolipoprotein A-I (ApoA-I) variants with murine adipocytes and macrophages. J Biol Chem 268(4): 2616-2622.

Edelstein C, Davidson NO & Scanu AM (1994) Oleate stimulates the formation of triglyceride-rich particles containing apoB100-apo(a) in long-term primary cultures of human hepatocytes. Chem Phys Lipids 67-68:135-143.

Ehnholm C, Lukka M, Kuusi T, Nikkilä E & Utermann G (1986) Apolipoprotein E polymorphism in the Finnish population: gene frequencies and relation to lipoprotein concentrations. J Lipid Res. 27(3): 227-235.

Ericsson CG, Hamsten A, Nilsson J, Grip L, Svane B & de Faire U (1996) Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 347: 849-853.

Folch J, Lees M & Sloane Stanley GH (1957) A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 226: 497-509.

Forte TM, Goth-Goldstein R, Nordhausen RW & McCall MR (1993) Apolipoprotein A-I-cell membrane interaction:extracellular assembly of heterogenous nascent HDL particles. J Lipid Res 34: 317-324.

Freeman DJ, Griffin BA, Murray E, Lindsay GM, Gaffney D, Packard CJ & Shepherd J (1993) Smoking and plasma lipoproteins in man: effects on low density lipoprotein cholesterol levels and high density lipoprotein subfraction distribution. Eur J Clin Invest 23(10): 630-640.

Frick MH, Dahlén G, Berg K, Valle M & Hekali P (1978) Serum lipids in angiographically assessed coronary atherosclerosis. Chest 73: 62-65.

Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V, Mäenpää H, Mälkönen M, Mänttäri M, Norola S, Pasternack A, Pikkarainen J, Romo M, Sjöblom T & Nikkilä EA (1987) Helsinki Heart Study: primary-prevention trial with gemfibrozil an middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, andincidence of coronary heart disease. N Engl J Med 317:1237-1245.

Friedewald WT, Levy RI & Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical Chemistry 18:499-502.

Funke H (1997) Genetic determinants of high density lipoprotein levels. Curr Opin Lipidol 8(3):189-96.

Föger B, Wohlfarter T, Ritsch A, Lechleitner M, Miller CH, Dienstl A & Patsch JR (1994) Kinetics of lipids, apolipoproteins, and cholesteryl ester transfer protein in plasma after a bicycle marathon. Metabolism 43(5): 633-639.

Gajra, B, Candlish JK, Saha N, Heng CK, Soemantri AG & Tay JS (1994) Influence of polymorphisms for apolipoprotein B (ins/del, XbaI, EcoRI) and apolipoprotein E on serum lipids and apolipoproteins in a Javanese population. Genet Epidemiol 11(1):19-27.

Gaw A & Hobbs HH (1994) Molecular genetics of lipoprotein (a): new pieces to the puzzle. Curr Opin Lipidol 5:149-155.

Gaw A, Packard CJ, Lindsay GM, Murray EF, Griffin BA, Caslake MJ, Colquhoun I, Wheatley DJ, Lorimer AR & Shepherd J (1996) Effects of colestipol alone and in combination with simvastatin on apolipoprotein B metabolism. Arterioscler Thromb Vasc Biol 16:236-249.

Genest JJ Jr, Ordovas JM, McNamara JR, Robbins AM, Meade T, Cohn SD, Salem DN, Wilson PW, Masharani U, Frossard PM & Schaefer EJ (1990) DNA polymorphisms of the apolipoprotein B gene in patients with premature coronary artery disease. Atherosclerosis 82(1-2):7-17.

Goldstein JL & Brown MS (1989) Familial Hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS and Valle D (eds) The metabolic basis of inherited disease. McGraw-Hill, Inc., New York, p 1215-1250.

Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR Jr, Bangdiwala S & Tyroler HA (1989) High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79: 8-15.

Grass GM, Sweetana SA & Bozarth CA (1990) The effects of enprostil and RS-86505-007 on in-vitro intestinal permeability of rabbit and monkey. J Pharm Pharmacol 42:40-45.

Groener JEM, Pelton RW & Kostner GM (1986) Improved estimation of cholesteryl ester transfer/exchange activity in serum or plasma. Clin Chem 32(2): 283-286.

Guérin M, Dolphin PJ, Talussot C, Gardette J, Berthézène F & Chapman, MJ (1995) Pravastatin modulates cholesteryl ester transfer from HDL to apoB-containing lipoproteins and lipoprotein subspecies profile in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 15:1359-1368.

Gupta AK, Ross EA, Myers JN & Kashyap ML (1993) Increased reverse cholesterol transport in athletes. Metabolism 42(6): 684-690.

Gurakar A, Hoeg JM, Kostner G, Papadopoulos NM & Brewer HB Jr (1985) Levels of lipoprotein Lp(a) decline with neomycin and niacin treatment. Atherosclerosis 57: 293-301.

Hallman DM, Boerwinkle E, Saha N, Sandholzer C, Menzel HJ, Csázár A & Utermann G (1991) The apolipoprotein E polymorphism: a comparison of allele frequencies and effects in nine populations. Am J Hum Genet 49: 338-349.

Hamsten A, Walldius G, Szamosi A, Dahlen G & de Faire U (1986) Relationship of angiographically defined coronary artery disease to serum lipoproteins and apolipoproteins in young survivors of myocardial infarction. Circulation 73(6): 1097-1110.

Hannuksela M, Marcel YL, Kesäniemi YA & Savolainen MJ (1992) Reduction in the concentration and activity of plasma cholesteryl ester transfer protein by alcohol. J Lipid Res 33: 737-744.

Hansen PS, Gerdes LU, Klausen IC, Gregersen N & Faergeman O (1993) Polymorphisms in the apolipoprotein B-100 gene contributes to normal variation in plasma lipids in 464 Danish men born in 1948. Hum Genet 91(1): 45-50.

Havel RJ, Eder HA & Bragdon JH (1955) The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 34: 1345-1353.

Hegele RA, Huang LS, Herbert PN, Blum CB, Buring JE, Hennekens CH & Breslow JL (1986) Apolipoprotein B-gene DNA polymorphisms associated with myocardial infarction. N Engl J Med 315(24): 1509-1515.

Hobbs HH, Russell DW, Brown MS & Goldstein JL (1990) The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein. Annu Rev Genet 24: 133-170.

Hobbs HH, Brown MS, and Goldstein JL (1992) Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum Mutat 1: 445-466

Holmquist L & Carlson K (1977) Selective extraction of human serum very low density apolipoproteins with organic solvents. Biochim Biophys Acta 493(2): 400-409

Homma Y, Ozawa H, Kobayashi T, Yamaguchi H, Sakane H & Nakamura H (1995) Effects of simvastatin on plasma lipoprotein subfractions, cholesterol esterification rate, and cholesteryl ester transfer protein in type II hyperlipoproteinemia. Atherosclerosis 114(2): 223-234.

Huang Y, von Eckardstein A, Wu S & Assmann G (1995) Effects of the apolipoprotein E polymorphism in uptake and transfer of cell-derived cholesterol in plasma. J Clin Invest 96: 2693-2701

Humphries SE & Talmud PJ(1995) Hyperlipidaemia associated with genetic variation in the apolipoprotein B gene. Curr Opin Lipidol 6(4): 215-222.

Hämäläinen T, Palotie A, Aalto-Setälä K, Kontula K & Tikkanen MJ (1990) Absence of familial defective apolipoprotein B-100 in Finnish patients with elevated serum cholesterol. Atherosclerosis 82(3):177-183.

Höstmark AT, Osland A, Simonsen S & Levorstad, K (1990) Lipoprotein-related coronary risk factors in patients with angiographically defined coronary artery disease: relation to number of stenosed arteries. J Int Med 228: 317-321.

Illingworth DR (1988) An overview of lipid-lowering drugs. Drugs 36 suppl 3:63-71.

Innerarity TL, Mahley RW, Weisgraber KH, Bersot TP, Krauss RM, Vega GL, Grundy SM, Friedl W, Davignon J & McCarthy BJ (1990) Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia. J Lipid Res 31(8): 1337-1349.

Jenner K, Sidoli A, Ball M, Rodriguez JC, Pagani F, Giudici G, Vergani C, Mann J, Baralle FE & Shoulders CC (1988) Characterization of genetic markers in the 3" end of the apo B gene and their use in family and population studies. Atherosclerosis 69: 39-49.

Johansson S, Bondjers G, Fager G, Wedel H, Tsipogianni A, Olofsson S, Vedin A, Wiklund O & Wilhelmsson C (1988) Serum lipids and apolipoprotein levels in women with acute myocardial infarction. Arteriosclerosis 8: 742-749.

Kane JP (1983) Apolipoprotein B: structural and metabolic heterogeneity. Annu Rev Physiol 45: 637-650.

Kauppinen-Mäkelin R & Nikkilä EA (1988) Serum lipoproteins in patients with myocardial infarction. Atherosclerosis 74: 65-74.

Keesler GA, Li Y, Skiba PJ, Fless GM & Tabas I (1994) Macrophage foam cell lipoprotein(a)/apoprotein(a) receptor Cell-surface localization, dependence of induction on new protein synthesis, and ligand specificity. Arterioscler Thromb 14: 1337-1345.

Kesäniemi YA, Ehnholm C & Miettinen TA (1987) Intestinal cholesterol absorption efficiency in man is related to apoprotein E phenotype. J Clin Invest 80(2): 578-581.

Kinoshita M, Arai H, Fukasawa M, Watanabe T, Tsukamoto K, Hashimoto Y, Inoue K, Kurokawa K & Teramoto T (1993) Apolipoprotein E enhances lipid exchange between lipoproteins mediated by cholesteryl ester transfer protein. J Lipid Res 34(2): 261-268.

Kleinveld HA, Demacker PN, De Haan AF & Stalenhoef AF (1993) Decreased in vitro oxidizability of low-density lipoprotein in hypercholesterolaemic patients treated with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors . Eur J Clin Invest 23(5): 289-295.

Knott TJ, Pease RJ, Powell LM, Wallis SC, Rall SC Jr, Innerarity TL, Blackhart B, Taylor WH, Marcel Y, Milne R, Johnson D, Fuller M, Lusis AJ, McCarthy BJ, Mahley RW, Levy-Wilson B & Scott J (1986) Complete protein sequence and identification of structural domains of human apolipoprotein B. Nature 323: 734-738.

Koivisto PV, Koivisto UM, Kovanen PT, Gylling H, Miettinen TA & Kontula K (1993) Deletion of exon 15 of the LDL receptor gene is associated with a mild form of familial hypercholesterolemia FH-Espoo. Arteriosclerosis & Thrombosis 13(11): 1680-1688.

Koivisto UM & Kontula K (1996) A novel deletion/inversion mutation in the low-density lipoprotein receptor gene as a cause of heterozygous familial hypercholesterolemia. Human Mutation 8(4): 326-32.

Koivisto UM, Viikari JS & Kontula K (1995) Molecular characterization of minor gene rearrangements in Finnish patients with heterozygous familial hypercholesterolemia: identification of two common missense mutations (Gly823-->Asp and Leu380-->His) and eight rare mutations of the LDL receptor gene. Am J of Hum Genetics 57(4): 789-797.

Koivisto UM, Turtola H, Aalto-Setälä K, Top B, Frants RR, Kovanen PT, Syvänen AC & Kontula K (1992) The familial hypercholesterolemia (FH)-North-Karelia mutation of the low density lipoprotein receptor gene deletes seven nucleotides of exon 6 and is a common cause of FH in Finland. J Clin Invest 90: 219-228.

Kuusi T, Nieminen MS, Ehnholm C, Yki-Järvinen H, Valle M, Nikkilä EA & Taskinen MR (1989) Apoprotein E polymorphism and coronary artery disease Increased prevalence of apolipoprotein E-4 in angiographically verified coronary patients. Arteriosclerosis 9(2): 237-241.

Lackner C, Boerwinkle E, Leffert CC, Rahmig T & Hobbs HH (1991) Molecular basis of apolipoprotein (a) isoform size heterogeneity as revealed by pulsed-field gel electrophoresis. J Clin Invest 87: 2153-2161.

Lagrost L, Florentin E, Guyard-Dangremont V, Athias A, Gandjini H, Lallemant C & Gambert P (1995) Evidence for nonesterified fatty acids as modulators of neutral lipid transfers in normolipidemic human plasma. ArteriosclerThrombVascBiol 15(9): 1388-1396.

Langer T, Strober W & Levy R (1972) The metabolism of low density lipoprotein in familial type II hypercholesterolemia. J Clin Invest 51: 1528-1536.

Law SW, Grant SM, Higuchi K, Hospattankar A, Lackner K, Lee N & Brewer HB Jr (1986) Human liver apolipoprotein B-100 cDNA: complete nucleic acid and derived amino acid sequence. Proc Natl Acad Sci USA 83(21): 8142-8146.

Lechleitner M, Miesenbock G & Patsch JR (1990) HDL cholesterol, triglycerides and coronary heart disease. Curr Opin Lipidol 1: 330-333.

Lehtimäki T, Moilanen T, Porkka K, Åkerblom HK, Rönnemaa T, Räsänen L, Viikari J, Ehnholm C & Nikkari T (1995) Association between serum lipids and apolipoprotein E phenotype is influenced by diet in a population-based sample of free-living children and young adults: the Cardiovascular Risk in Young Finns Study. J Lipid Res 36: 653-661.

Leren TP, Berg K, Hjermann I & Leren P (1988) Further evidence for an association between the XbaI polymorphism at the apolipoprotein B locus and lipoprotein level. Clin Genet 34(6): 347-351.

Lipid Research Clinics Program The Lipid Research Clinics Coronary Primary Prevention Trial results I (1984a) Reduction in incidence of coronary heart disease. JAMA 251(3): 351-364.

Lipid Research Clinics Program The Lipid Researsh Clinics Coronary Primary Prevention Trial results II (1984b) The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 251: 365-374.

Lowry OH, Rosebrough NJ, Farr AL & Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275.

Luc G, Bard JM, Arveiler D, Evans A, Cambou JP, Bingham A, Amouyel P, Schaffer P, Ruidavets JB, Cambien F, Fruchart JC & Ducimetiere P (1994) Impact of apolipoprotein E polymorphism on lipoproteins and risk of myocardial infarction The ECTIM Study. ArteriosclerThromb 14(9): 1412-1419.

Ludwig EH, Blackhart BD, Pierotti VR, Caiati L, Fortier C, Knott T, Scott J, Mahley RW, Levy-Wilson B & McCarthy BJ (1987) DNA sequence of the human apolipoprotein B gene. DNA 6(4): 363-372.

Luria MH, Erel J, Sapoznikov D & Gotsman MS (1991) Cardiovascular risk factor clustering and ratio of total cholesterol to high-density lipoprotein cholesterol in angiographically documented coronary artery disease. Am J Cardiol 67: 31-36.

Ma YH, Schumaker VN, Butler R & Sparkes RS (1987) Two DNA restriction fragment length polymorphisms associated with Ag(t/z) and Ag(g/c) antigenic sites of human apolipoprotein B. Arteriosclerosis 7(3): 301-305.

Maher V, Sinfuego J, Chao P & Parekh J (1997) Primary prevention of coronary heart disease What has WOSCOPS told us and what questions remain? Drugs 54(1): 1-8.

Maher VMG & Brown BG (1995) Lipoprotein (a) and coronary heart disease. Curr Opin Lipidol 6: 229-235.

Mahley RW (1988) Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 240(4852): 622-630.

Mahley RW, Innerarity TL, Rall SC Jr, Weisgraber KH & Taylor JM (1990) Apolipoprotein E: genetic variants provide insights into its structure and function. Curr Opin Lipidol 1: 87-95.

Marcel YL, McPherson R, Hogue M, Czarnecka H, Zawadzki Z, Weech PK, Whitlock ME, Tall AR & Milne RW (1990) Distribution and concentration of cholesteryl ester transfer protein in plasma of normolipemic subjects. J Clin Invest 85(1): 10-17.

Martin LJ, Connelly PW, Nancoo D, Wood N, Zhang ZJ, Maguire G, Quinet E, Tall AR, Marcel YL & McPherson R (1993) Cholesteryl ester transfer protein and high density lipoprotein responses to cholesterol feeding in men: relationship to apolipoprotein E genotype. J Lipid Res 34(3): 437-446.

Martin MJ, Hulley SB, Browner WS, Kuller LH & Wentworth D (1986) Serum cholesterol, blood pressure and mortality: implications from a cohort of 361 662 men. Lancet ii: 933-936.

Matthews CME (1957) The theory of tracer experiments with iodine-131-labelled plasma proteins. Phys Med Biol 2: 36-53.

McFarlane AS (1958) Efficient trace-labeling of proteins with iodine. Nature(Lond) 53: 182.

McPherson R, Mann CJ, Tall AR, Hogue M, Martin L, Milne RW & Marcel YL (1991) Plasma concentrations of cholesteryl ester transfer protein in hyperlipoproteinemia Relation to cholesteryl ester transfer protein activity and other lipoprotein variables. Arterioscler Thromb 11(4): 797-804.

Menzel HJ & Utermann G (1986) Apolipoprotein E phenotyping from serum by Western blotting. Electrophoresis 7: 492-495.

Miettinen T A, Gylling H, Vanhanen H & Ollus A (1992) Cholesterol absorption, elimination, and synthesis related to LDL kinetics during varying fat intake in men with different apoprotein E phenotypes. Arterioscler Thromb 12:1044-1052.

Miller SA, Dykes DD & Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acid Res 16: 1215.

Miserez AR, Laager R, Chiodetti N & Keller U (1994) High prevalence of familial defective apolipoprotein B-100 in Switzerland. J Lipid Res 35(4): 574-583.

Monsalve MV, Young R, Jobsis J, Wiseman SA, Dhamu S, Powell JT, Greenhalgh RM & Humphries SE (1988) DNA polymorphisms of the gene for apolipoprotein B in patients with peripheral arterial disease. Atherosclerosis 70(1-2): 123-129.

Multiple Risk Factor Intervention Trial Research Group (1986) Relationship between baseline risk factors and coronary heart disease and total mortality in the Multiple Risk Factor Intervention Trial. Prev Med 15: 254-273.

Murai A, Miyahara T, Fujimoto N, Matsuda M & Kameyama M (1986) Lp(a) lipoprotein as a risk factor for coronary heart disease and cerebral infarction. Atherosclerosis 59: 199-204.

Mänttäri M, Koskinen P, Ehnholm C, Huttunen JK & Manninen V (1991) Apolipoprotein E polymorphism influences the serum cholesterol response to dietary intervention. Metabolism 40(2): 217-221.

Nieminen MS, Mattila KJ, Aalto-Setälä K, Kuusi T, Kontula K, Kauppinen-Mäkelin R, Ehnholm C, Jauhiainen M, Valle M & Taskinen MR (1992) Lipoproteins and their genetic variation in subjects with and without angiographically verified coronary artery disease. Arterioscler Thromb 12(1): 58-69.

Ojala JP, Helve E, Ehnholm C, Aalto-Setälä K, Kontula KK & Tikkanen MJ (1991) Effect of apolipoprotein E polymorphism and XbaI polymorphism of apolipoprotein B on response to lovastatin treatment in familial and non-familial hypercholesterolemia. J Intern Med 230: 397-405.

Olsson AG & Mölgaard J (1988)The future pharmacological therapy for risk factor reduction: Hyperlipidaemia. Drugs 36 suppl 3:115-120.

O`Malley J P & Illingworth DR (1990) The influence of apolipoprotein E phenotype on the response to lovastatin therapy in patients with heterozygous familial hypercholesterolemia. Metabolism 39(2):150-154.

Paulweber B, Friedl W, Krempler F, Humphries SE & Sandhofer F (1990) Association of DNA polymorphism at the apolipoprotein B gene locus with coronary heart disease and serum very low density lipoprotein levels. Arteriosclerosis 10(1): 17-24.

Peacock R, Dunning A, Hamsten A, Tornvall P, Humphries S & Talmud P (1992) Apolipoprotein B gene polymorphisms, lipoproteins and coronary atherosclerosis: a study of young myocardial infarction survivors and healthy population-based individuals. Atherosclerosis 92(2-3): 151-164.

Priestley L, Knott T, Wallis S, Powell L, Pease R, Brunt H & Scott J (1985) RFLP for the human apolipoprotein B gene: V;XbaI. Nucleic Acids Res 13(18): 6793.

Pullinger CR, Hennessy LK, Chatterton JE, Liu W, Love JA, Mendel CM, Frost PH, Malloy MJ, Schumaker VN & Kane JP (1995) Familial ligand-defective apolipoprotein B Identification of a new mutation that decreases LDL receptor binding affinity. J Clin Invest 95(3):1225-1234.

Rainwater DL (1995) Genetic basis for multimodal relationship between apolipoprotein (a) size and lipoprotein (a) concentration in Mexican-Americans. Atherosclerosis 115: 165-171.

Rajput-Williams J, Knott TJ, Wallis SC, Sweetnam P, Yarnell J, Cox N, Bell GI, Miller NE & Scott J (1988) Variation of apolipoprotein-B gene is associated with obesity, high blood cholesterol levels and increased risk of coronary heart disease. Lancet ii: 1442-1446.

Reaven GM, Swislocki AL, Jeng CY, Hollenbeck CB, Schwartz K & Chen YD (1988) Effect of enprostil on plasma glucose, insulin and lipid metabolism in patients with non-insulin dependent diabetes mellitus. Horm Metab Res 20:633-636.

Rhoads GG, Dahlen G, Berg K, Morton NE & Dannenberg AL (1986) Lp(a) lipoprotein as a risk factor for myocardial infarction. JAMA 256(18): 2540-2544.

Richards EG, Grundy SM & Cooper K (1989) Influence of plasma triglycerides on lipoprotein patterns in normal subjects and in patients with coronary artery disease. Am J Cardiol 63: 1214-1220.

Roberts WC (1992) Atherosclerotic risk factors- are there ten, or is there only one? Atherosclerosis 97 suppl S5-S9.

Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR & Braunwald E (1996)The effect of pravastating on coronary events after myocardial infarction in patients with average cholesterol levels Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335 (14) : 1001-9.

Sakai N, Yamashita S, Hirano K, Ishigami M, Arai T, Kobayashi K, Funahashi T & Matsuzawa Y (1995) Decreased affinity of low density lipoprotein (LDL) particles for LDL receptors in patients with cholesteryl ester transfer protein deficiency. Eur J Clin Invest 25(5): 332-339.

Sandholzer C, Hallman DM, Saha N, Sigurdsson G, Lackner C, Császár A, Boerwinkle E & Utermann G (1991) Effects of the apolipoprotein (a) size polymorphism on the lipoprotein (a) concentration in 7 ethnic groups. Hum Genet 86: 607-614.

Sandholzer C, Saha N, Kark JD, Rees A, Jaross W, Dieplinger H, Hoppichler F, Boerwinkle E and Utermann G (1992) Apo(a) isoforms predict risk for coronary heart disease A study in six populations. Arterioscler Thromb 12: 1214-1226.

Savolainen MJ, Hannuksela M, Seppänen S, Kervinen K & Kesäniemi YA (1990) Increased high-density lipoprotein cholesterol concentration in alcoholics is related to low cholesteryl ester transfer protein activity. Eur J Clin Invest 20(6): 593-599.

Savolainen MJ, Rantala M, Kervinen K, Järvi L, Suvanto K, Rantala T & Kesäniemi YA (1991) Magnitude of dietary effects on plasma cholesterol concentration: role of sex and apolipoprotein E phenotype. Arteriosclerosis 86: 145-152.

Scandinavian Simvastatin Survival Study Group (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383-1389.

Schaefer EJ, Lamon-Fava S, Jenner JL, McNamara J, Ordovas, JM Davis E, Abolafia JM, Lippel K & Levy RI (1994) Lipoprotein(a) levels and risk of coronary heart disease in men The Lipid Research Clinics Coronary Primary Prevention Trial. JAMA 271: 999-1003.

Schuster H, Rauh G, Kormann B, Hepp T, Humphries S, Keller C, Wolfram G & Zöllner N (1990) Familial defective apolipoprotein B-100 Comparison with familial hypercholesterolemia in 18 cases detected in Munich. Arteriosclerosis 10(4): 577-581.

Schwartz KE, Zaro B, Burton P, Hunt J, Pennelly L & Sevelius H (1988) Reduction of serum lipoproteins in man by the oral administration of a prostaglandin analogue (enprostil). Atherosclerosis 71: 9-16.

Schwartz KE & Saito T (1989) Suppression of alimentary lipemia in man by a prostaglandin analogue (enprostil). Atherosclerosis 79: 231-236.

Sehayek E, Butbul E, Avner R, Levkovitz H & Eisenberg S (1994) Enhanced cellular metabolism of very low density lipoprotein by simvastatin A novel mechanism of action of HMG-CoA reductase inhibitors. Eur J Clin Invest 24(3): 173-178.

Seip RL, Moulin P, Cocke T, Tall A, Kohrt WM, Mankowitz K, Semenkovich CF, Ostlund R & Schonfeld G (1993) Exercise training decreases plasma cholesteryl ester transfer protein. ArteriosclerThromb 13(9): 1359-1367.

Shepherd, J Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, McKillop JH & Packard CJ (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia West of Scotland Coronary Prevention Study Group. New Engl J Med 333(20): 1301-1307.

Simons LA (1993) Simvastatin in severe primary hypercholesterolemia: efficacy, safety, and tolerability in 595 patients over 18 weeks The principal investigators. Clin Cardiol 16: 317-322.

Snyder ML, Hay RV, Whitington PF, Scanu AM & Fless GM (1994) Binding and degradation of lipoprotein(a) and LDL by primary cultures of human hepatocytes Comparison with cultured human monocyte-macrophages and fibroblasts. Arterioscler Thromb 14: 770-779.

Soria LF, Ludwig EH, Clarke HR, Vega GL, Grundy SM & McCarthy BJ (1989) Association between a specific apolipoprotein B mutation and familial defective apolipoprotein B-100. Proc Natl Acad Sci USA 86(2): 587-591.

Stampfer MJ, Sacks FM, Salvini S, Willett WC & Hennekens CH (1991) A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. New Engl J Med 325: 373-381.

Stuyt PM, Brenninkmeijer BJ, Demacker PN, Hendriks JC, van Elteren P, Stalenhoef AF & van "t Laar A (1991) Apolipoprotein E phenotypes, serum lipoproteins and apolipoproteins in angiographically assessed coronary heart disease. Scand J Clin Lab Invest 51(5): 425-435.

Sullivan AK, Holdright DR, Wright CA, Sparrow JL, Cunningham D & Fox KM (1994) Chest pain in women: clinical, investigative, and prognostic features. BMJ 308: 883-886.

Tall A (1995) Plasma lipid transfer proteins. Annu Rev Biochem 64: 235-257.

Talmud PJ, Barni N, Kessling AM, Carlsson P, Darnfors C, Bjursell G, Galton D, Wynn V, Kirk H, Hayden MR & Humphries SE (1987) Apolipoprotein B gene variants are involved in the determination of serum cholesterol levels: a study in normo- and hyperlipidaemic individuals. Atherosclerosis 67(1): 81-89.

Tato F, Vega GL & Grundy SM (1995b) Bimodal distribution of cholesteryl ester transfer protein activities in normotriglyceridemic men with low HDL cholesterol concentrations. Arterioscler Thromb Vasc Biol 15(4): 446-451.

Tató F, Vega GL, Tall AR & Grundy SM (1995a) Relation between cholesterol ester transfer protein activities and lipoprotein cholesterol in patients with hypercholesterolemia and combined hyperlipidemia. Arterioscler Thromb Vasc Biol 15(1): 112-120.

Teng B, Sniderman AD, Soutar AK & Thompson GR (1986) Metabolic basis of hyperapobetalipoproteinemia Turnover of apolipoprotein B in low density lipoprotein and its precursors and subfractions compared with normal and familial hypercholesterolemia. J Clin Invest 77: 663-672.

Thompson GR, Maher VMG, Matthews S, Kitano Y, Neuwirth C, Shortt MB, Davies G, Rees A, Mir A, Prescott RJ, de Feyter P & Henderson A (1995) Familial Hypercholesterolemia regression study: a randomised trial of low-density-lipoprotein apheresis. Lancet 345: 811-816.

Thompson GR (1996) A handbook of hyperlipidaemia. Current Science Ltd, London, p 118.

Thompson GR, Seed M, Niththyananthan S, McCarthy S & Thorogood M (1989) Genotypic and phenotypic variation in familial hypercholesterolemia. Arteriosclerosis 9(suppl 1): I-75-I-80.

Tikkanen MJ & Heliö T (1992) Genetic variants of apolipoprotein B: relation to serum lipid levels and coronary artery disease among the Finns. Ann Med 24(5): 357-361.

Tiret L, de Knijff P, Menzel HJ, Ehnholm C, Nicaud V & Havekes LM (1994) ApoE polymorphism and predisposition to coronary heart disease in youths of different European populations The EARS study. Arterioscler Thromb 14(10):1617-1624.

Tybjaerg-Hansen A, Gallagher J, Vincent J, Houlston R, Talmud P, Dunning AM, Seed M, Hamsten A, Humphries SE & Myant NB (1990) Familial defective apolipoprotein B-100: detection in the United Kingdom and Scandinavia, and clinical characteristics of ten cases. Atherosclerosis 80: 235-242.

Tybjaerg-Hansen A, Nordestgaard BG, Gerdes LU & Humphries SE (1991) Variation of apolipoprotein B gene is associated with myocardial infarction and lipoprotein levels in Danes. Atherosclerosis 89(1): 69-81.

Ukkola O, Kervinen K, Salmela PI, von Dickhoff K, Laakso M & Kesäniemi YA (1993a) Apolipoprotein E phenotype is related to macro- and microangiopathy in patients with non-insulin-dependent diabetes mellitus. Atherosclerosis 101: 9-15.

Ukkola O, Savolainen MJ, von Dickhoff K & Kesäniemi YA (1993b) Apolipoprotein B gene DNA polymorphisms are associated with macro- and microangiopathy in non-insulin-dependent diabetes mellitus. Clin Genet 44(4): 177-184.

Utermann G (1987) Apolipoprotein E polymorphism in health and disease. Am Heart J 113:433-440.

Utermann G, Hardewig A & Zimmer F (1984) Apolipoprotein E phenotypes in patients with myocardial infarction. Hum Genet 65: 237-241.

Utermann G, Menzel HJ, Kraft HG, Duba HC, Kemmler HG & Seitz C (1987) Lp(a) glycoprotein phenotypes Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J Clin Invest 80:458-465.

Vega GL & Grundy SM (1986) In vivo evidence for reduced binding of low density lipoproteins to receptors as a cause of primary moderate hypercholesterolemia. J Clin Invest 78: 1410-1414.

Wang XL, McCredie RM & Wilcken DEL (1995) Polymorphisms of the apolipoprotein E gene and severity of coronary artery disease defined by angiography. Arterioscler Thromb Vasc Biol 15: 1030-1034.

Watts GF, Cummings MH, Umpleby M, Quiney JR, Naoumova R, Thompson GR & Sönksen PH (1995) Simvastatin decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolaemia: pathophysiology and therapeutic implications. Eur J Clin Invest 25(8): 559-567.

Woo J, Lau E, Lam CWK, Kay R, Teoh R, Wong HY, Prall WY, Kreel L & Nicholls MG (1991) Hypertension, lipoprotein(a), and apolipoprotein A-I as risk factors for stroke in the Chinese. Stroke 22: 203-208.

Wu JH, Wen MS, Lo SK & Chern MS (1994) Increased frequency of apolipoprotein B signal peptide sp24/24 in patients with coronary artery disease General allele survey in the population of Taiwan and comparison with Caucasians. Clin Genet 45(5): 250-254.

Xu CF, Nanjee N, Tikkanen MJ, Huttunen JK, Pietinen P, Bütler R, Angelico F, Del Ben M, Mazzarella B, Antonio R, Miller NG, Humphries SE & Talmud PJ (1989) Apolipoprotein B amino acid 3611 substitution from arginine to glutamine creates the Ag (h/i) epitope: the polymorphism is not associated with differences in serum cholesterol and apolipoprotein B levels. Hum Genet 82(4): 322-326.

Young SG (1990) Recent progress in understanding apolipoprotein B. Circulation 82(5): 1574-1594.

Zannis VI, Breslow JL, Utermann G, Mahley R, Weisgraber KH, Havel RJ, Goldstein JL, Brown MS, Schonfeld G, Hazzard WR & Blum C (1982) Proposed nomenclature of apoE isoproteins, apoE genotypes, and phenotypes. J Lipid Res 23: 911-914.